Nanjing King-Friend Biochemical Pharma News and Activities

Nanjing King-Friend Biochemical Pharma is one of the...

• CSI 500;
• TOB Iconic 10,000.

Nanjing King-Friend Biochemical Pharma is a company listed under the stock ticker 603707 (CN).

View the org chart displaying its 8 main executives

Most searched biographies at Nanjing King-Friend Biochemical Pharma

• Yongqun Tang, Chairman of The Board and General Manager
• Juhua Xie, Director
• Guoqing Cui, Independent Director

Create your alert
to follow the executive moves at Nanjing King-Friend Biochemical Pharma.

Nanjing King-Friend Biochemical Pharma has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Corden Pharma has announced the acquisition of AmbioPharm  (posted on June 5 2026).
• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Nanjing King-Friend Biochemical Pharma

Social media about Nanjing King-Friend Biochemical Pharma

• Nanjing King-Friend Biochemical Pharma on Wikipedia, Google News & Yahoo Finance
• Nanjing King-Friend Biochemical Pharma on LinkedIn, X (Twitter) & YouTube